

# ***In vitro* antidiabetic activity of mushroom *Coprinus comatus* water extract**

Nebojša P Stilinović<sup>1</sup>, Saša N Vukmirović<sup>1</sup>, Ana D Tomas Petrović<sup>1</sup>, Siniša S Babović<sup>2</sup>, Boris M Veskov<sup>3</sup>, Aleksandar L Rašković<sup>1</sup>



<sup>1</sup>Department of Pharmacology and Toxicology, Faculty of Medicine Novi Sad, University of Novi Sad

<sup>2</sup>Department of Anatomy, Faculty of Medicine Novi Sad, University of Novi Sad

<sup>3</sup>Krka-Farma d.o.o. Belgrade

Sekcija za kliničku farmakologiju Srpskog lekarskog društva „dr Srđan Đani Marković”



**INTRODUCTION:** It is proven that mushroom *Coprinus comatus* has many pharmacological activities, including antidiabetic. One of the mechanisms of antidiabetic activity may be the inhibition of enzymes responsible for carbohydrates metabolism, such as  $\alpha$ -amylase and  $\alpha$ -glucosidase and dipeptidyl peptidase-4. Therefore, in this study the activity of these enzymes after their inhibition with *C. comatus* extract was examined.

**AIM OF WORK:** The aim of this study was to examine *in vitro* activity of aqueous extract of mushroom *C. comatus* on previously mentioned enzymes.

**METHODS:** As a sample it was used The sample of the commercial preparation of mushroom was used for making of an aqueous extract, which is then lyophilised. Inhibitory activity for  $\alpha$ -amylase and  $\alpha$ -glucosidase and dipeptidyl peptidase-4 was measured in triplicate by spectrophotometric methods.

**RESULTS:** Examined water extract of *C. comatus* mushroom showed dose-dependent inhibition of all tested enzymes. Compared to positive controls (acarbose and sitagliptin) the extract was used in much higher concentrations in order to achieve 50% inhibition of enzymes  $\alpha$ -amylase,  $\alpha$ -glucosidase and dipeptidyl peptidase-4.

**CONCLUSION:** Based on the results of study it can be concluded that although it was achieved 50% inhibition of enzyme activity with use of *C. comatus* mushroom extract, it is not sufficient to explain its antidiabetic activity. Therefore, it is necessary to examine additional mechanisms, or to make other extract formulations in order to confirm *in vivo* mushroom activity.

**Acknowledgment:** The results presented here are obtained within projects No. 41012 and 172050 supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia.

